Efficient and accurate end-to-end solution for rare disease cases

Author:

QIAGEN Digital Insights

Efficient and accurate end-to-end solution for rare disease cases

Human Genome Variation Society (HGVS) is hosting a meeting on “Clinical Interpretation of Variants from Next-Generation Sequencing”. The meeting will take place on May 20, 2016 in Barcelona and will explore multiple aspects of the clinical use of NGS.

We’re very much looking forward to participate and Dr. Sohela Shah, Principal Genome Scientist for Advanced Testing at QIAGEN Bioinformatics, will present on how our end-to-end clinical solution can benefit your work:

An efficient and accurate end-to-end solution leveraging network analytics to infer patient syndrome and identify causal mutations in rare disease cases

Session 2, 11.50 a.m. – 12.10 p.m.

Our hereditary disease solution is widely adopted, with unsurpassed comprehensiveness of validated content and accuracy. It integrates the entire analysis to insight workflow and allows you to easily analyze, discover, and interpret the causal agents of the disease.

Read more about our hereditary disease solution
Get more details about HGVS